University of California

Fujisawa Pharmaceutical Company, Ltd.

Panasonic Intellectual Property Management Co., Ltd.

Astellas Pharma Gmbh

Naoaki Fujii

David Jablons

Liang You

Kiyoshi Taniguchi

Biao He

Minoru Sakurai

Zhidong Xu

Yasuyo Tomishima

Hisashi Takasugi

Akira Tanaka

Kouji Hattori

Irwin D Kuntz

David Hugh Stokoe

R Kiplin Guy

Rodney Kiplin Guy

Kumi Hosoi

Hajime Sogabe

Hirofumi Ishikawa

Naomi Hanioka

Jose Haresco

Kathleen P Novak

Masayoshi Murata

Hiroshi Kayakiri

Hitoshi Hamashima

Satoru Kuroda

Osamu Okitsu

Hiroaki Ohtake

Kenichi Washizuka

Yusuke Iwamatsu

Masashi Imanishi

Yutaka Nakajima

Fujiko Takamura

Mie Nishio

Satoshi Koyama

David M Jablons

A first controller controls the DC-DC converter to perform a step-up operation when a voltage on the DC bus is lower than a first reference voltage and controls the DC-DC converter to suspend the step-up operation when the voltage is equal to or higher than the first reference voltage. A second controller controls the inverter to maintain the voltage on the DC bus constant when the voltage on the DC bus is lower than a second reference voltage and controls the inverter to maximize an output power of the inverter when the voltage is equal to or higher than the second reference voltage.

Power converter

Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formula (I) or (III). The invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl), inhibiting Wnt signaling.

Small molecule inhibition of PDZ-domain interaction

Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formula (I) or (III) The invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl), inhibiting Wnt signaling. 

This invention provides compositions, methods and kits for the diagnosis and treatment of cancers expressing a GLI polypeptide, and in particular a GLI1, GLI2 or GLI3 polypeptide. The invention provides small molecule compounds mimicking the transcriptional activation domain of a GLI polypeptide. The small molecule inhibitors of the invention specifically block the activator function of a GLI polypeptide, but not the repressor function of GLI3.

Targeting GLI proteins in human cancer by small molecules

Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formula  The invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl); inhibiting Wnt signaling.

Small molecule inhibition of a PDZ-domain interaction

This invention relates to new propanolamine derivatives or salts thereof represented by the following formula [I]: Wherein each symbol is as defined in the specification or salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.

Propanolamine derivatives

The present invention relates to a compound formula (I) wherein X is bond or &mdash;O&mdash;CH &mdash;, (II) or (III) R is hydrogen or an amino protective group, a is phenyl, indolyl or carbazolyl, each of which may be substituted with one or two substituent(s), and B is hydrogen; halogen; lower alkyl; lower alkoxycarbonyl; cyclo(lower)alkyl; or a heterocyclic group, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzyl or phenyl, each of which may be substituted with one or two substituent(s), or a salt thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiures or urinary incontinence.

Aminoalcohol derivatives

4,5-diaryloxazole compounds

Oxazole compounds useful as PGE2 agonists and antagonists

Growing community of inventors

South San Francisco, CA, United States of America

Naoaki Fujii